AB

Alexis Borisy

Life Sciences Entrepreneur and Investor

Greater Boston

Overview 

Alexis Borisy is a highly accomplished life sciences entrepreneur and investor based in Greater Boston, known for founding and leading successful companies such as EQRx and Relay Therapeutics. With a Master's degree from Harvard University and a Bachelor's degree from the University of Chicago, Borisy has held key roles including Founder & Executive Chairman at EQRx and Co-Founder and Chairman at Relay Therapeutics, showcasing his expertise in building and growing innovative biotech ventures.

Work Experience 

  • Co-Founder & Chairman

    2022 - Current

Curie.Bio is a founder-focused seed-stage venture capital firm.

  • Board Member

    2022

  • Co-Founder

    2022

  • Founder & Executive Chairman

    2021

  • Founder, Chairman, and CEO

    2020 - 2021

  • Co-Founder and Chairman

    2016

  • Co-Founder and CEO

    2016 - 2017

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

Raised $1,400,000,000.00 from Nextech Invest.

  • Chairman Of The Board

    2017

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Raised $351,000,000.00 from Casdin Capital, RA Capital Management, Woodline Partners, Boxer Capital, EcoR1 Capital, Surveyor Capital, Farallon Capital Management, Avoro Capital Advisors, Gilead Sciences and Samsara BioCapital.

  • Founding Investor & Board Member

    2014

Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.

Raised $2,004,400,000.00 from Nextech Invest, Boxer Capital, Schroder Adveq, Cormorant Capital, Casdin Capital, Vivo Capital, Biotechnology Value Fund, Deerfield Capital Management, Third Rock Ventures and Fidelity.

  • Co-Founder and Director

    2010

  • Interim CEO

    2013 - 2014

Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.

Raised $2,367,800,000.00 from Royalty Pharma, Sixth Street and Cowen Investment Management.

  • Board Of Directors

    2019 - 2021

  • Partner

    2010 - 2019

Articles About Alexis

Relevant Websites